Integra Lifesciences (IART) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Integra Lifesciences (IART) do?
Integra Lifesciences Holdings Corp (IART) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures regenerative tissue technologies, electrosurgical devices, and surgical instruments. Produces collagen-based implants and specialized surgical tools used in brain surgery and wound repair. It is worth $1.05B on the market and sold $1.65B over the last year.
- Market cap
- $1.05B
- P/E ratio
- 82.4×
- Annual sales
- $1.65B
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 18, 2026
Brands and businesses behind IART
- Codman: Provides neurosurgical access tools, micro-instruments, and intracranial pressure monitors sold directly to hospital operating rooms.
- DuraGen: Supplies collagen dural graft matrices that seal brain tissue and prevent cerebrospinal fluid leaks after head surgeries.
- CUSA: Markets ultrasonic tissue ablation systems used by neurosurgeons to selectively remove soft tissue tumors.
- Mayfield: Sells rigid skull clamp systems that hold a patient head securely in place during delicate brain surgery.
- SurgiMend: Manufactures bovine collagen matrices used to reinforce soft tissue during complex plastic and reconstructive operations.
IART’s flags, in plain English
Each flag is a number from Integra Lifesciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 3.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Cheap on Cash Flow
Priced at 12.3 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Wide Gross Margin
Gross margin of 54.9% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Debt Is Driving
Heavy debt, 188% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about IART
How big is Integra Lifesciences?
Integra Lifesciences’ market cap is $1.05B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.65B: what customers paid the company over the last year, before any costs.
What is IART’s P/E ratio?
IART’s P/E ratio is 82.4×. Investors pay about 82.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with IART?
Manufacturing quality compliance issues at key production sites have previously halted operations and triggered costly product recalls. That is one risk on Integra Lifesciences’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Integra Lifesciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. IART’s filings on SEC.gov. The Margin Monkey is research, not advice.
